Helping Our Global Partners Respond to the SARS-COV-2 Pandemic Is Our Number One Priority
BioLegend has committed its capabilities, resources, and immunology expertise to work that directly addresses the SARS-CoV-2 crisis. With the first reports of COVID-19, we took immediate action to keep our employees safe, maintain essential operations, and accelerate the development of key products to ensure our partners have the tools they need to survey, treat, and monitor the outbreak within our communities. We have ramped-up and expanded production of our multiplex cytokine/chemokine detection kits (LEGENDplex™) and flow cytometry reagents designed to monitor the immune status of COVID-19 patients. We are also developing new antibody-oligonucleotide reagents (TotalSeq™ antibody panels for proteogenomics) optimized to provide a comprehensive understanding of pulmonary immune responses to the coronavirus.
We are working closely with experts across the scientific and medical communities to advance testing and treatment. We are committed to see this through together!
Applied Research – BioLegend is partnering with top East Coast Medical Research Institutes using TotalSeq antibodies to analyze immune responses to SARS-CoV-2 at a single-cell RNA and protein level in the lungs of over 100 infected individuals.
Diagnostic Testing – Investigators in Asia are using BioLegend antibodies to develop SARS-CoV-2 immunoglobulin assays. By measuring the levels of these antibodies, investigators are able to identify previously infected persons and monitor antibody production levels, regardless of whether the individual is still infected or has recovered from the disease.
Clinical Drug Trials – Researchers and clinicians in New York, France and Spain are using LEGENDplex kits and BioLegend’s Flow Cytometry antibodies to monitor 'cytokine storm' and immune responses of COVID-19 patients receiving novel treatments in immunotherapy and multidrug clinical trials.
Vaccine Trials – National Labs are using TotalSeq, soluble HLA monomers and tetramers (Flex-T™), conjugated antibodies, and custom antibodies to characterize the immune response to candidate SARS-CoV-2 vaccines which are currently in human testing.
We want to hear from you
BioLegend is collaborating with researchers and clinicians just like you. Whether you are in the lab, working remotely, or finding new ways to work, we are here to help. Tell us how we can partner with you to fight COVID-19 by submitting your information on our Tools for SARS-Cov-2 Research page.